ArticleFrontiers in endocrinology2026
Exploration of potential mechanisms and biomarkers related to ERS-associated RCD in steroid-induced osteonecrosis of the femoral head based on bioinformatics, with experimental validation.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The pathogenesis of osteonecrosis of the femoral head (ONFH) is associated with endoplasmic reticulum stress (ERS) and regulated cell death (RCD), but reliable linking biomarkers and their mechanisms remain unclear. This study aimed to screen SONFH biomarkers related to ERS/RCD and explore their mechanisms. Methods: Using datasets from public databases on ONFH, ERS-related genes (ERGs), and RCD-related genes (RRGs), candidate genes were isolated by intersecting the differentially expressed genes (DEGs) with the ERG and RRG sets. We identified biomarkers by integrating a protein-protein interaction (PPI) network, four computational algorithms, and machine learning, with results refined by the Wilcoxon rank-sum test. The diagnostic power of these biomarkers was assessed using receiver operating characteristic (ROC) curve analysis. A subsequent comprehensive investigation included constructing and evaluating a nomogram, along with analyses of pathway enrichment, immune infiltration, drug prediction, and molecular docking, culminating in experimental validation. Results: Initially, the 100 candidate genes were identified. After multi-step screening, 2 biomarkers (TGFB1, MCL1) were finally determined. Both were significantly upregulated in the ONFH group (p < 0.05), and the area under the ROC curve (AUC) of both was greater than 0.85. The constructed nomogram showed good predictive accuracy (AUC = 0.897, Hosmer-Lemeshow test p = 0.171) and had a net benefit greater than zero, indicating good clinical practicality. These biomarkers were enriched in pathogen-related pathways, correlated with immune cells such as plasmacytoid dendritic cells, and exhibited good molecular docking effects with domperidone (Vina score ≤ -7.7 kcal/mol). RT-qPCR and western blot validation in GC-treated cell models (BMSC, BMEC, THP-1) confirmed significant upregulation of both TGFB1 and MCL1, consistent with the bioinformatics findings. Conclusion: TGFB1 and MCL1 could serve as potential SONFH biomarkers related to ERS/RCD. The nomogram, as well as the two biomarkers' regulatory and immune associations, provided a reference for ONFH diagnosis. Domperidone shows potential as a candidate drug for the targeted therapy of ONFH, although its clinical application remains pending
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.